US 11,786,531 B1
Methods of treating B-cell proliferative disorder
Jason Paik, Cambridge, MA (US); Tommi Salmi, Cambridge, MA (US); and Ying Ou, Cambridge, MA (US)
Assigned to BeiGene Switzerland GmbH, Basel (CH)
Filed by BeiGene Switzerland GmbH, Basel (CH)
Filed on Jan. 19, 2023, as Appl. No. 18/98,938.
Claims priority of provisional application 63/366,053, filed on Jun. 8, 2022.
Claims priority of provisional application 63/383,503, filed on Nov. 13, 2022.
Claims priority of provisional application 63/383,504, filed on Nov. 13, 2022.
Claims priority of provisional application 63/384,864, filed on Nov. 23, 2022.
Claims priority of provisional application 63/387,796, filed on Dec. 16, 2022.
Int. Cl. A61K 31/52 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/52 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 30 Claims
OG exemplary drawing
 
1. A method of treating or delaying progression of a B-cell proliferative disorder in a patient receiving a moderate CYP3A inducer, the method comprising
concomitantly administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, at a total daily dose of about 640 mg, and the moderate CYP3A inducer,
wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or follicular lymphoma (FL).